Introduction. Megalencephalic leukoencephalopathy with subcortical cysts is a rare disease with autosomal recessive inheritance. Materials and methods. Two br others born from a consanguineous marriage, presenting wit...
详细信息
Introduction. Megalencephalic leukoencephalopathy with subcortical cysts is a rare disease with autosomal recessive inheritance. Materials and methods. Two br others born from a consanguineous marriage, presenting with the phenotype of the disease, their parents, brothers and sisters were examined. Magnetic resonance imaging of the brain was performed for the two patients. sequence analysis of ML C1 (GenBank mRNA accession no. NM 015166) was performed for the patients using i ntronic primers. PCR restriction fragment length polymorphism analysis was done in patients, their parents and in 100 Lebanese controls in order to exclude gene ***. The clinical features were characteristic of the disease, consisting of an early-onset macrocephaly followed by slowly progressive ataxia , pyramidal tract involvement and epileptic seizures. In one patient, the clinic al manifestations were aggravated by a trivial brain trauma. In his brother and in one female cousin, a status epilepticus was precipitated by a febrile syndrom e. The diffuse cerebral white matter lesions and the subcortical temporo-polar and frontal cysts, best seen on MRI,allowed making the *** genet ics revealed a new mutation involving the MLC1 gene (263G→T, exon 3). As a cons equence, it affects the second transmembrane domain predict (G88V) of the MLC pr otein (protein sequence NP 055981). The mutation was confirmed by PCR restrictio n fragment length polymorphism analysis. Conclusion. Megalencephalic leucoenceph alopathy with subcortical cysts may be individualized on clinical and radiologic al basis and confirmed by molecular genetics. In this Lebanese family, a new mut ation of the MLC1 gene is reported.
BACKGROUND Endoscopic sleeve gastroplasty(EsG) is an effective therapy for class Ⅰ-Ⅱ obesity, but there are knowledge gaps in the published literature about its implementation in patients with class Ⅲ obesity [body...
详细信息
BACKGROUND Endoscopic sleeve gastroplasty(EsG) is an effective therapy for class Ⅰ-Ⅱ obesity, but there are knowledge gaps in the published literature about its implementation in patients with class Ⅲ obesity [body mass index(BMI) ≥ 40 kg/m2].AIM To evaluate the safety, clinical efficacy, and durability of EsG in adults with class Ⅲ *** This was a retrospective cohort study that used prospectively collected data on adults with BMI ≥ 40 kg/m2who underwent EsG and longitudinal lifestyle counseling at two centers with expertise in endobariatric therapies from May 2018-March 2022. The primary outcome was total body weight loss(TBWL) at 12 mo. secondary outcomes included changes in TBWL, excess weight loss(EWL) and BMI at various time points up to 36 mo, clinical responder rates at 12 and 24 mo, and comorbidity improvement. safety outcomes were reported through the study duration. One-way ANOVA test was performed with multiple Tukey pairwise comparisons for TBWL, EWL, and BMI over the study *** 404 consecutive patients(78.5% female, mean age 42.9 years, mean BMI 44.8 ± 4.7 kg/m2) were enrolled. EsGs were performed using an average of 7 sutures, over 42 ± 9 min, and with 100% technical success. TBWL was 20.9 ± 6.2% at 12 mo, 20.5 ± 6.9% at 24 mo, and 20.3 ± 9.5% at 36 mo. EWL was 49.6 ± 15.1% at 12 mo, 49.4 ± 16.7% at 24 mo, and 47.1 ± 23.5% at 36 mo. There was no difference in TBWL at 12, 15, 24, and 36 mo from EsG. TBWL exceeding 10%, 15%, and 20% was achieved by 96.7%, 87.4%, and 55.6% of the cohort at 12 mo, respectively. Of the cohort with the relevant comorbidity at time of EsG, 66.1% had improvement in hypertension, 61.7% had improvement in type Ⅱ diabetes, and 45.1% had improvement in hyperlipidemia over study duration. There was one instance of dehydration requiring hospitalization(0.2% serious adverse event rate).CONCLUsION When combined with longitudinal nutritional support, EsG induces effective and durable weight loss in adults with c
目的发布欧洲重症医学学会(European society of Intensive Care Medicine, EsICM)关于神经重症监护患者液体治疗的专家共识和临床实践推荐意见。设计在2016年10月召开的EsICM LIVE 2016会议上召集了一个由22名国际专家组成的共识委员会...
详细信息
目的发布欧洲重症医学学会(European society of Intensive Care Medicine, EsICM)关于神经重症监护患者液体治疗的专家共识和临床实践推荐意见。设计在2016年10月召开的EsICM LIVE 2016会议上召集了一个由22名国际专家组成的共识委员会,随后委员会成员通过电话会议和在线讨论制定本专家共识。方法回顾人群、干预、对比和结局(population, intervention,comparison, and outcomes, PICO)问题,根据需要进行更新并得到证据概要。本共识关注3个主要议题:(1)神经重症监护患者的液体复苏和维持;(2)高渗液体在颅内压控制中的应用;(3)蛛网膜下腔出血后迟发性脑缺血的液体管理。经过广泛的文献检索,应用推荐分级的评估、制订与评价(Gradingof Recommendations Assessment, Development and Evaluation, GRADE)系统原则评估证据质量(从高到极低),制定治疗推荐(强或弱),并在适用时发布最佳实践声明。基于文献和专家意见提供的综合证据,应用改良德尔菲方法(使用序贯方法以避免偏倚和误解)产生最终共识声明。结果最终共识包含总共32条声明,其中13条为强推荐,17条为弱推荐,另外2条声明未提供推荐意见。结论我们发布了一份关于神经重症监护患者液体治疗的共识声明和临床实践推荐。
暂无评论